



Pharmacy Formulary Updates for June 2018

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. The changes below are reflected in our online drug list.

The following is a list of drugs that changed formulary status in June 2018:

Drug Name	Tufts Health Plan Commercial Formularies		
	Tufts Health Freedom Plan		
	Large Group 3-Tier Formulary	Large Group 4-Tier Formulary	Small Group/Individual 4-Tier (Exchange Formularies)
Norvir tablets	T2 (no change)		NC
ritonavir tablets	T2		
Zavesca	T3;PA (no change)	T4;PA (no change)	NC
miglustat	T3;PA		
Erleada	T2;PA;SP	T4;PA;SP	
Rebinyn	MB;PA;SI		
Biktarvy	T2		
Bevyxxa	T3;QL		
Imbruvica tablets	T2;PA	T4;PA	
Cimduo	T2		
Symfi	T2		
Symfi Lo	T2		
Zypitamag	NC		
celecoxib	T2		
Biltricide tablets	T3 (no change)		NC
praziquantel tablets	T2		
Donnatal elixer	Excluded		
phenobarbital- hyoscyamine – atropine sulfate- scopolamine Hbr (16.2-0.1037-0.0194-0.0065 mg/5mL) elixer	Excluded		

Key:

MM		Managed Mail – must fill at mail order pharmacy	
NC	Not covered	SP	Specialty Pharmacy
PA	Prior Authorization	ST^{PA}	Step Therapy Prior Authorization
QL	Quantity Limitation	MB	Medical Benefit